Access cutting-edge meningiomas treatment through this clinical trial at a research site in Birmingham. Study-provided care at no cost to qualified participants.
Access meningiomas specialists in Birmingham at no cost
This study follows strict safety protocols and ethical guidelines
All study-related meningiomas treatment provided free
This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with meningioma that is growing, spreading, or getting worse (progressive). Vismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Sponsor: Alliance for Clinical Trials in Oncology
Check if you qualify for this meningiomas clinical trial in Birmingham, AL
If you're searching for meningiomas treatment options in Birmingham, AL, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Birmingham research site is actively enrolling participants for this clinical trial. You'll receive care from experienced meningiomas specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.